EUVIMEDEUVIMED entdecken
BeobachtungsstudieStudienprotokollOpen Access · CC BY-NC 4.0

Protocol of a Real‐World Prospective Observational Study of Amivantamab Plus Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Non‐Small Cell Lung Cancer ( SPIRAL ‐ RACER20 Study)

Ryo Sawada iD, Tadaaki Yamada iD, Takayuki Shimose, Masaki Ishida iD, Hayato Kawachi, Naoya Nishioka iD, Masahiro Iwasaku iD, Shinsaku Tokuda, Tohru Inaba iD, Koichi Takayama iD

Thoracic Cancer · 2026-11 · 17 (21)

DOI: 10.1111/1759-7714.70414 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Thoracic Cancer, online erschienen am 05.11.2026. Verfasst von Ryo Sawada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The PAPILLON trial demonstrated that amivantamab plus carboplatin and pemetrexed was superior to chemotherapy alone in treatment‐naive patients with epidermal growth factor receptor exon 20 insertion–positive non‐small cell lung cancer (EGFR exon 20 insertion–positive NSCLC). However, a substantial proportion of patients encountered in routine practice would not meet the eligibility criteria of pivotal clinical trials. Consequently, the effectiveness and safety of this regimen remain insufficiently characterized under real‐world conditions, especially among Japanese patients. This study was designed to assess the effectiveness and safety of amivantamab plus chemotherapy in routine clinical practice and to explore biomarkers associated with treatment efficacy and prognosis in patients with EGFR exon 20 insertion–positive NSCLC.

Methods

SPIRAL‐RACER20 is a multicenter, prospective, noninterventional observational study enrolling patients with advanced or recurrent EGFR exon 20 insertion–positive NSCLC who are scheduled to receive amivantamab plus carboplatin and pemetrexed as part of routine clinical care. The primary endpoint is the 1‐year progression‐free survival (PFS) rate, while secondary endpoints include median PFS, objective response rate (ORR), time to treatment failure (TTF), safety profile, and the real‐world management of dermatologic toxicities. Exploratory biomarker analyses will be conducted using blood‐based next‐generation sequencing (NGS) before treatment and at treatment discontinuation or completion in patients who provide consent.

Discussion

This study will generate prospective real‐world evidence on amivantamab‐based therapy in patient populations underrepresented in registration trials. Trial Registration: Japan Registry of Clinical Trials, jRCT1071250104; registered 28 November 2025

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansProspective StudiesErbB ReceptorsFemaleExonsMale

Stichwörter der Autor:innen

EGFR exon 20 insertionamivantamabliquid biopsynon‐small cell lung cancerprospective observational study

Substanzen

ErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Statistics and Data Center, Clinical Research Support Center Kyushu, Fukuoka, Japan.
  • Kyoto Prefectural Institute of Public Health and Environment, Kyoto, Japan.
  • Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.

ORCID-Profile: Ryo Sawada, Tadaaki Yamada, Masaki Ishida, Naoya Nishioka, Masahiro Iwasaku, Tohru Inaba, Koichi Takayama

Zitieren

APA

Sawada, R., Yamada, T., Shimose, T., Ishida, M., Kawachi, H., Nishioka, N., Iwasaku, M., Tokuda, S., Inaba, T., & Takayama, K. (2026). Protocol of a Real‐World Prospective Observational Study of Amivantamab Plus Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Non‐Small Cell Lung Cancer ( SPIRAL ‐ RACER20 Study). Thoracic Cancer, 17(21). https://doi.org/10.1111/1759-7714.70414

Vancouver

Sawada R, Yamada T, Shimose T, Ishida M, Kawachi H, Nishioka N, et al. Protocol of a Real‐World Prospective Observational Study of Amivantamab Plus Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Non‐Small Cell Lung Cancer ( SPIRAL ‐ RACER20 Study). Thoracic Cancer. 2026;17(21). doi:10.1111/1759-7714.70414

BibTeX
@article{Sawada2026,
  author = {Sawada, Ryo and Yamada, Tadaaki and Shimose, Takayuki and Ishida, Masaki and Kawachi, Hayato and Nishioka, Naoya and Iwasaku, Masahiro and Tokuda, Shinsaku and Inaba, Tohru and Takayama, Koichi},
  title = {Protocol of a Real‐World Prospective Observational Study of Amivantamab Plus Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Non‐Small Cell Lung Cancer ( SPIRAL ‐ RACER20 Study)},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {21},
  doi = {10.1111/1759-7714.70414}
}
Kostenlos starten →